Strategic partnerships Claret Bioscience has actively pursued collaborations in sequencing with Singulargenomics, validating its library preparation assays for the G4 sequencer. This indicates openness to co-development and external validation, presenting opportunities to propose joint projects or pilot collaborations with complementary sequencing platforms.

Early-stage growth As a Santa Cruz based, early-stage biotech startup with a small team, Claret is likely seeking strategic hires, fundraising support, and scalable contract manufacturing or CRO partnerships to accelerate development of ssDNA library prep and fragmentomics algorithms.

Innovation focus The company emphasizes novel NGS library preparation approaches and fragmentomics for cancer detection, liquid biopsies, FFPE, and ancient DNA, signaling a need for advanced assay design, computational biology support, and potential licensing of proprietary algorithms to industry partners.

Functional tech stack Utilizing tools like Sage Intacct, HubSpot Analytics, Microsoft 365, OpenAI, and KnowBe4 suggests readiness for modern CRM, finance, and AI-enabled data workflows. This can be leveraged to propose integrated data analytics, automation, or AI-assisted research services.

Market positioning With revenue in the $1M–$10M range and a focus on niche sequencing applications, Claret may be seeking strategic customers or partners in precision oncology, liquid biopsy diagnostics, and ancient DNA testing, as well as potential investors or accelerators that support ultra-early biotech ventures.